Elixiron Immunotherapeutics (cayman) Limited · TPEX:7871

Elixiron Immunotherapeutics (cayman) — Yuanta Securities Pre-IPO Investor Conference 2026

40 slides from Elixiron Immunotherapeutics (cayman)'s conference presentation, Jun 4, 2026

Slide 1: Elixiron Immunotherapeutics (Cayman) Limited
ELIXIR 7 Bo ae A APRA) ELEM RTS Pc al =~ iron Immunotherapeutics (Cayman) Limited
Slide 2: RAR AMES AA
RAR AMES AA 28/5 FREH Elixiron Immunotherapeutics (Cayman) Limited $17 SSR BHA APRA S) (RAM CARAS ) MH > SHREK AMA LM AAD HANMER AM > AAG RZAREAME UA UTBMTBAM > AMRAOS NRA ARHERA AMA TER BAMA MM > TERAHH RA WER A MISA + BR SUM SO Ath TAZHABRRER RAS HTAIRAA HEAR MBAR RK SAAB RAM MARL - RTO SLL Mem ZA
Slide 3: ELIXIRON &
ELIXIRON & - Qa HERB eA + [El-1071) Aixz3StECSF-LRIDGIA [ [ - [El-001) MiB FBAS HE + [El-012] MCD36H tink - S$Rithaee
Slide 4: Turn the Power of Healing On
RUBAS AHS HERA A) ELIXIRON @ DATE 77 5 | Sate Se ie a eel SE TURN THE POWER OF HEALING ON BA Hands Bess ees AIG GaRMEES AFirst-in-Class/ Best-in-Class SNZB# REM op PSK HR RRTE El-1071 CSF-1R #48) (ERPR—HA) Se) Aine E1001 (ETHER (BRK NA) CO) MBM ARAAR STE E1-001 MAE RAMB (2026E RK) Sc] Fe E1-012 CD36
Slide 5: HERTS Aha eRe
HERTS Aha eRe Q pestis sens 2024 RisiNe is [al 3 Bi A Se PART THE ALZHEIMER'S" MRNA Bile rel zz CLOUD ‘OASSOCIATION Moderna Talwon mRNA Innovation Awards 2020/2022 2024 Bi 2024 Bie 2025 BH eRe Taiwan BlOAwards 44 43imRNA $22 BHR FA 22 FR ar A SEMESRBE PEAT B aE AURA AAS fae ip |p Part the Cloud #& E
Slide 6: Part the Cloud
SARS : West Sh Ese me ePart.the Cloud 4 PART THE CLOUD Heather M. Snyder, Ph.D., Senior vice president, Alzheimer’s Association © part the Cloud BY en eS SERRA) AE ARIAIE > RRA RATED ANOS © PRA Part the Cloud BY 32 SAE MLS EREA CBIR AK > ARS PRL Be Elixiron > ZHRAGLA RS REE PERM > Bess) See SAS AAT
Slide 7: RARAws
RARAws SPU PER AMS > RRS TT3IARST aa Gamer — Affinity Capital By oman auananay es Hanes, DBRATL TECO RRES Qisda AAMAXPRO @|£EER et Daiwa Securities Group: DciPariners = DEXbG ra, Qrorre {87 SD RB A ELIXIRON @
Slide 8: AE Be as SA Bs BY OS DB
AE Be as SA Bs BY OS DB REN CROAT BEREMTRABER ASR on BRahts BAe lem t+ ATI 30A H ROARS RS Ast MEA BRARATRERLE PLES BIB AR (AEE 70% est be! IB jasc. RRKASTHR TE ene {SHIGA BLE 52% Udsp: cussions) & I BeiGene ae B WER TS BSE EGR PSS BSA Ps AL mB +t mst © First securities DB Seco BI (73 Fubon Financial
Slide 9: HEBER See RRRRAS A
HEBER See RRRRAS A FRERE AER Jean-Laurent Casanova#ii2 PERE SR Francisco Quintana #2 AML FHARHEMAS ESAME SAA hhmi ZHOGRAS MGH By thn 32 BeBe SSATP Oras FHMWAS BF ESB UCSan Diego ELIXIRON @
Slide 10: Winning Strategy
ELIXIR AS Rg Rein FBS WINNING STRATEGY
Slide 11: GSS RES : MRM RS eoh
11 GSS RES : MRM RS eoh ARR SATA, > TREES t/t SAUTE IE SEAARAR » LURE ©) woe ESSE mae ee * oN N86. aT BREESE ARG AREA ° S) ahs ROL SRARALESA Aleve miEw +t Abb + A AMAIA RN BR ean cheer RARER AGE $8 BIKAIS TAS ASR fi oe EBS Sei ABB Immunomodulation FAA PBPABAR BIRR SARS He Be Bas c ETE PIE S eRe BSt/
Slide 12: THAR EID : SF ATH ARED
THAR EID : SF ATH ARED — owt) A Fr lL i I if 1 BR RAPA REE ght Aa ae Rank 1/167 JEM BRE SHS AAT IF: 50 Shih et al., 2022 HSS ea SRST IF: 10.4 > = Tzenget al., 2023 SEARLE IF: 30.6 Changet al. 2023 Cell RATARHHL ESRF IF: 10.6 ScienceImmunology Top 5% Top 15% Penget al., 2025 RRAHAMELT IF: 16.3 RBA AH
Slide 13: CAO E A SE
CAO E A SE ScienceImmunology “JEM EER nature,, . Py medicine ® a FERS o TRAE AR First-in-class potential mis afstchavis > GRRL DAB 77 5S) = te tt Eon ; J | NARA First-in-Class Potential ( | senete nue zi if 9 ELIXIRON @
Slide 14: ine Rie eon
ine Rie eon BRASS : RUBRRAD REMAN ETE > WHEL RMASRBAALIS mB RMN (ERR SEE Discovery Preclinical Phasel Phaselll AEB T Orne IES oases Enrupatinib Me ° mee Buren \DF CSF-1R rie 4 ome PRESSE El-1071 4 @ Risse, | FOAMisemTE > onc Zz! Indemakitug wane wy © mavens ronments ES > EI-001 @ B% ! y, El-012 Be C
Slide 15: BESRKRALRDY : meReMe
BESRKRALRDY : meReMe ESR: FERPA > SAAS eIMA Rw 203345 SR nT BIS IE RR 5x ROFHBRRE 1 8x $240 Billions 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 15 SAATRZDBRRRRBEM > KES A BAAR AM aM a MASERRE REM EI-1071 Pe ZeiS EMS AesBBStE CSF-1R HMVGI (BRPR—HB) re. hoe ERE (a) 5 [RE HR AE 3S OB AA mea
Slide 16: EI-1071 (Enrupatinib)
ELIXIR El-1071 (Enrupatinib) Aes tt CSF-LREVB A 3 ETE: RSE. BRERA
Slide 17: Bi RE ROR CRA
Bi RE ROR CRA BR TH 18 Ae ae ' i , Bah tst at SEA BERRATR ROAGSUZARENBESA + El-1071 RMS FIBA + DRALHWELRASS > ABSSMRMASE + SES SRRABRMABASA - HERA Gladstone Institutes + GSK#EREAABS 4 Francisco Quintana fg pst 13) RDA BASAIE 4 HER Eo ea R Se ACL PBZRSMMZBRERe Part the Cloud#=###8i) 2020/2022 RHE > R
Slide 18: BAA MER > PZB ETE
BAA MER > PZB ETE Se ee ee eee ee mee (bit SBA PERILS BE EAI 5,500 MA > 2050 SEHWAG oe 3 — 7 AEA CRE D0EEREAR RHE APACS ESSBABEMESRSE ; AMBER : RARVSRAR > BRAHAM KEAVARSHRY > FDAROEMmAP Hee Li > HEREWEAR TE (bIREA30% > a aS le @ (Bi 7K AB 2Y /ASPHH nA FAR AARAZ BARS HH; ARIA-H/E) ) BRARMAIBIRA » HG
Slide 19: airway : EL-LOTIMM AHAB > RMA AEIC RAB
airway : EL-LOTIMM AHAB > RMA AEIC RAB AERP El-1L071 RF BA BARI v BSI A: ea cord. alee ¥ BRUM BRE EI-1071 Beebe ¥ PRES AA { CSF- AHEEME RB niccsie HMA GRE BTCSr- TRG BT ee A BL BAHCSF-1IRM GMA AA Hes tt ~—CSF-1RADAEY a Masitinible BLz945i61 PLX339714 ARG ELIXIRON @ janssen Ty © Daiiichi-Sankyo ‘moou
Slide 20: Base BASES ; Pnlsc eek ie ARR eT
Base BASES ; Pnlsc eek ie ARR eT Fe A Bia AR a eo v Pe ee PLS) RABBPRBUES (ats - = ¥ SePk—HARS PRESS emis) FAbt 2026S Avis) Pia Roe 4-week treatment 581 #RERS SSRI BR/SRMGA Se MSS (COBREL-1071 (Enrupatinib) LE BB) __ > « SE3BRERUEER: TSPO PET/MRI (ARRATSRA REMY) © MRBBSHSHRG + RBMRE - Aer » VACA EI-
Slide 21: ThiaeS : Re PLEAS SATE IB a
21 ThiaeS : Re PLEAS SATE IB a Bay 2k 8 BATE 78 AD Th be RSS FAH 20345 AB hy RRS BIB 3 30 (BTL APE RE 20: : sue Billion ) (USD l ‘iil ‘iil| ee ee } ABT ZR MRRR AS > AKA AMAR AMMA Bas > Ba 2 is BR ATE iT Be HF Hs SC Sra BAAR IB Ba PA BE PE SAAS 1B ABRREMELRRH tay) [eta TOM apener Grats man | AADEL EH
Slide 22: EI-001 (Indemakitug)
ELIXIR El-001 (Indemakitug) PMs Fie RS eins 3 ETE: ADDIE > IS < WAM AAR ATE
Slide 23: BY EE BL Ti
BY EE BL Ti RERIABR wT se El-001 SARE TERA HPMIGA RABE lEwm tet + El-001LS MS ABA + DRALRBRAER > ASHRVNASR BRAS Jean-Laurent Casanova #02 75) YY) Bench to Bedside: (#3 37 RR EE TI — BARR > SERRE SAAS TEAR esas! Faget Direct B Cloningtxii > Mme S AREER Stine E1001 FERED A ABR BAES > VIF EI-001 RAE BA
Slide 24: BRAMMER > ARE
BRAMMER > ARE ESR : RHBUARRG > RAMS > Shake Ams & seanonee ci saansxiem BRIA TRSBS (RT¥1-2% ) (A toeEe eeeee TTTTT patients with Monthly WTP Control vitiligo were § 2RSAZBREK vee (4 RBS te 201 BA) tT T TT 6 out of 10 ; patients to have depression reported a strong than peers" | | negative effect on
Slide 25: TAR TRAR ieiiadilene Rise Al A Mis TBR
TAR TRAR ieiiadilene Rise Al A Mis TBR IFN-y SRSRRR BB SIL Od TON DUA AROALRIEN-y BBE RE RMT MRAX Ni ENTREES MONIES BBemEee ° © RK wx SUE A SEER) Ay JAKE 1@) §1-001 ETE Re + SSeS | + RRR: 27920-3095 SEE SS MURS ; RRR + SERIE: FOAM; (RANBIR - RELA) hr . 4 @)€ Sy + @RAE KALE pee * a oe ~~ . set PA v5
Slide 26: BSS Behe : ARE RARR PR aE ITP
BSS Behe : ARE RARR PR aE ITP aA sss 4) EDA SE Schick TRESS SeRQ— RAR PRESS (omn/tsesene) SN N A 235 th GEOREAR E RIA (po, BROOME El-001 REA © BBR2HSt RY ¥ PRED BARR PR SLES (se . mee) FAR 2027 SSR ARRE 45 (ESHER S > HRD S24 eR 1 Endpoint Measurements & Safety Follow-up | Placebo (n= 15) + ERR AHET:
Slide 27: Manze (Wl : APEI-OOLFTIS RL ARE RIS thts eI YJ
Manze (Wl : APEI-OOLFTIS RL ARE RIS thts eI 45 YJ BHT (sn) ByAD Loe to) 1 -295f ~~ Keytruda ®@ Anti-PD1 mAb © merck 2 175f& Ozempic GLP 1 receptor agonist Be 3 1418 ~~ Dupixent @ Anti-IL4Ra SANOFI<% REGENERON 4 134f— —_Biktarvy HIV inhibitors @ciead 5 1338 =~ Eliquis Factor Xa inhibitor Z Bisel Myer
Slide 28: bLRE : AEA ReRAaR Ape
28 bLRE : AEA ReRAaR Ape ish : AME + WF BRS Sees RT aH HS 3c a PAR, SRRBRAR ER AARS > BBE ID ERR RR BSE ET AMERMRAARNR SES Crowding of major immunology indications: snapshot Q4/2023 a BLM EARS EM HE ON Fe nee ee anna nanan nnn nanan = Fryar apes x Peer us ‘ Sime AL} feces — 1 Be sos = 33 ’ H a veura
Slide 29: iS : —RS AH
iS : —RS AH FAREHE (vitiligo) Pathway-Driven » Aue MmBERRRETP 7 G) First-in-class potential } Drug Discovery RAGS Boat - Git ABR SHE (HH) AA RUE S BBE > EFDAMRRAR j9192026-cahh EI-001 MEF RE {«) Best-in-class potential } PAZ (Alopecia) > tRI2027TS RHI MR @ First-in-class potential } AAATRCHMARSH > A
Slide 30: EAA AR HE : RSH AS A
EAA AR HE : RSH AS A {FS BURES : PURER ERASE LE > FAS Re NR bH BARE ER iestse rl > STRAT LOE TBR MAb - MES RAF AR BEC \ MEI AM RAR SHE PRB RAR Aey > GIR PAM TBAT zits amemawe voemifane @SODI E1-001 #8988 ELIXIRON @ emapalumab-tzsg VY ELOOLLMRBER SRLS ts - eBIEA 200 =, Sai iRiRSobi PABA V CHES IFDAMI
Slide 31: EI-012 (PLT012)
ELIXIR El-012 (PLTO12) #iCD36 thinks 3 ETE: ERE hs Ber
Slide 32: ARRAS > SESS APR Ea RATE
ARRAS > SESS APR Ea RATE SiRRRARRIRGT : SUBRERERUS ROR LudwigiEDIET AR BRUR EMA E> FRNUCSNEMOURT AE CO36{1 HERSEY > Frannie (e ] — ST ee RR | ee Ee eo le a RBI ie. La. EO Se SS FR RMA : HERMES > ASS RAE ) BALE E1012: CDIGHHAMMB O First-in-ctass potential MSH BRC SE He 20234 2025%F ERAA SAMETIOR CANC
Slide 33: Vision 2030: Strategic Roadmap
ELIXIR Se ect al Sa eS VISION 2030: STRATEGIC ROADMAP
Slide 34: FAA on Se CEE
34 FAA on Se CEE >) EAICSRRS : RANE REE SMASH ast > Hat STA som R028 eee Lhe a SA Se 8.b5/.biG iw a ee ee ee | E1-1071 BRM LS RE atzheimers WS xR BBS BR WELTER EI-001 " ———————— saan > SMe Ae) = HAE 1 bn ORF RHA > > roy) FOAM RLM B= MEER 1 ban ERHA E1-001 ARB > | —_— EVER = HACER E1-012 a b> ——»>>——
Slide 35: SB B-KY wets: 7871
SB B-KY wets: 7871 — RHARRFAHREREMBEAA BPs kRee Bm AMER MAS RELRES RS FRARAES SRAM TILT SERA BEM A ESA a PA RERS ES BRAM BAER MEA A SIS RITMA SARA TR 35 SAT ZHBHRRLEE > KA AAMABRMR CHR ZAMAMMEES - SARAARMSRBADAL RRS HT RABARRBER SARMSSRAHARMME > UTKAADNAR LHR LER KE © FHA AR wees RiSOhSS BHCE RARE t
Slide 36: ESA SEAS}
ESA SEAS} REE Sees)
Slide 38: Stee
Stee 5 EE SE
Slide 39: “HLS ER > = .
“E1071. E!-001 ’ “HLS ER > = .
Slide 40: Contact Us
ELIXIRON & a sete sh 3 se cay ! Contact Us © ir@elixiron.com (*) www.elixiron.com Boston CIC Cambridge — Taipei Bioinnovation Park Elixiron Immunotherapeutics (Cayman) Limited

Elixiron Immunotherapeutics (Cayman) — Yuanta Securities Pre-IPO Investor Conference 2026 on 6ix

Elixiron Immunotherapeutics (cayman) — Yuanta Securities Pre-IPO Investor Conference 2026

Slide 1: Elixiron Immunotherapeutics (Cayman) Limited

Slide 2: RAR AMES AA

Slide 3: ELIXIRON &

Slide 4: Turn the Power of Healing On

Slide 5: HERTS Aha eRe

Slide 6: Part the Cloud

Slide 7: RARAws

Slide 8: AE Be as SA Bs BY OS DB

Slide 9: HEBER See RRRRAS A

Slide 10: Winning Strategy

Slide 11: GSS RES : MRM RS eoh

Slide 12: THAR EID : SF ATH ARED

Slide 13: CAO E A SE

Slide 14: ine Rie eon

Slide 15: BESRKRALRDY : meReMe

Slide 16: EI-1071 (Enrupatinib)

Slide 17: Bi RE ROR CRA

Slide 18: BAA MER > PZB ETE

Slide 19: airway : EL-LOTIMM AHAB > RMA AEIC RAB

Slide 20: Base BASES ; Pnlsc eek ie ARR eT

Slide 21: ThiaeS : Re PLEAS SATE IB a

Slide 22: EI-001 (Indemakitug)

Slide 23: BY EE BL Ti

Slide 24: BRAMMER > ARE

Slide 25: TAR TRAR ieiiadilene Rise Al A Mis TBR

Slide 26: BSS Behe : ARE RARR PR aE ITP

Slide 27: Manze (Wl : APEI-OOLFTIS RL ARE RIS thts eI YJ

Slide 28: bLRE : AEA ReRAaR Ape

Slide 29: iS : —RS AH

Slide 30: EAA AR HE : RSH AS A

Slide 31: EI-012 (PLT012)

Slide 32: ARRAS > SESS APR Ea RATE

Slide 33: Vision 2030: Strategic Roadmap

Slide 34: FAA on Se CEE

Slide 35: SB B-KY wets: 7871

Slide 36: ESA SEAS}

Slide 37: He th FF Ahi H

Slide 38: Stee

Slide 39: “HLS ER > = .

Slide 40: Contact Us